How is Ebola virus disease treated?
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Treatment of Ebola Virus Disease: Current Strategies and Emerging Therapies
Supportive Care for Ebola Virus Disease
Fluid Resuscitation and Electrolyte Management
The cornerstone of Ebola virus disease (EVD) treatment is supportive care, which primarily involves fluid resuscitation and correction of electrolyte imbalances. This approach is essential to manage dehydration and prevent complications such as shock . Patients often require intravenous fluids, electrolyte supplementation, and monitoring of vital signs to stabilize their condition.
Critical Care Interventions
In severe cases, patients may develop life-threatening complications, including hypotension, acute kidney injury, metabolic acidosis, and respiratory failure. These conditions necessitate critical care interventions such as intravenous vasoactive medications, renal replacement therapy, and mechanical ventilation . Advanced supportive care has significantly improved survival rates in patients treated in high-resource settings.
Experimental Therapies for Ebola Virus Disease
Antiviral Agents
Several experimental antiviral agents have shown promise in treating EVD. Favipiravir (T-705) has been associated with improved survival rates and significant reductions in viral load in clinical studies . Another antiviral, remdesivir, was evaluated in a randomized controlled trial but did not demonstrate superiority over other treatments.
Monoclonal Antibodies
Monoclonal antibody therapies, such as ZMapp, MAb114, and REGN-EB3, have been tested for their efficacy in reducing mortality from EVD. In a clinical trial, MAb114 and REGN-EB3 were found to be superior to ZMapp in reducing mortality rates, leading to their recommendation for further use. These therapies work by targeting specific viral proteins, thereby neutralizing the virus and aiding the immune response.
Convalescent Plasma
The use of convalescent plasma, derived from survivors of EVD, has been explored as a treatment option. While it has shown some potential, its efficacy remains uncertain, and there are risks such as transfusion-related acute lung injury. Further research is needed to establish its role in EVD treatment.
Vaccine Development and Prophylaxis
Vaccine Strategies
Vaccination is a critical component of EVD prevention. Several vaccine candidates are in various stages of development, with some showing promising results in early trials. One notable strategy involves using recombinant vesicular stomatitis virus as a delivery vector, which has demonstrated efficacy in both preexposure and postexposure prophylaxis .
Conclusion
The treatment of Ebola virus disease relies heavily on supportive care to manage symptoms and prevent complications. Experimental therapies, including antiviral agents and monoclonal antibodies, have shown promise in improving survival rates. Vaccination remains a key strategy for preventing EVD outbreaks. Continued research and clinical trials are essential to develop and refine these treatment options, ultimately improving outcomes for patients affected by this deadly disease.
Sources and full results
Most relevant research papers on this topic